Amdocs Limited (NASDAQ:DOX – Get Free Report) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $61.64 and traded as high as $62.05. Amdocs shares last traded at $61.40, with a volume of 1,316,848 shares changing hands.
Wall Street Analyst Weigh In
DOX has been the topic of a number of analyst reports. KeyCorp began coverage on Amdocs in a research report on Monday, June 29th. They issued a “sector weight” rating on the stock. Cfra lowered Amdocs to a “sell” rating in a research report on Thursday, May 14th. Wall Street Zen downgraded Amdocs from a “buy” rating to a “hold” rating in a report on Sunday, July 5th. Stifel Nicolaus cut their target price on Amdocs from $88.00 to $71.00 and set a “buy” rating on the stock in a research note on Thursday, May 14th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Amdocs in a research report on Wednesday, August 5th. Three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Amdocs presently has an average rating of “Hold” and a consensus target price of $86.67.
View Our Latest Analysis on Amdocs
Amdocs Price Performance
Amdocs Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a dividend of $0.569 per share. This represents a $2.28 annualized dividend and a dividend yield of 3.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Amdocs’s payout ratio is presently 54.29%.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DOX. Pzena Investment Management LLC grew its position in Amdocs by 82.6% in the 4th quarter. Pzena Investment Management LLC now owns 12,037,015 shares of the technology company’s stock worth $969,100,000 after purchasing an additional 5,443,766 shares during the period. Alyeska Investment Group L.P. lifted its holdings in shares of Amdocs by 155.1% during the 4th quarter. Alyeska Investment Group L.P. now owns 2,110,393 shares of the technology company’s stock valued at $169,908,000 after buying an additional 1,283,231 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Amdocs by 19.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 3,463,797 shares of the technology company’s stock worth $226,045,000 after buying an additional 571,036 shares during the last quarter. Squarepoint Ops LLC boosted its stake in shares of Amdocs by 469.4% in the 4th quarter. Squarepoint Ops LLC now owns 543,875 shares of the technology company’s stock worth $43,787,000 after buying an additional 448,358 shares during the last quarter. Finally, Voloridge Investment Management LLC grew its holdings in shares of Amdocs by 501.1% in the fourth quarter. Voloridge Investment Management LLC now owns 520,494 shares of the technology company’s stock worth $41,905,000 after acquiring an additional 433,907 shares during the period. Institutional investors own 92.02% of the company’s stock.
About Amdocs
Amdocs (NASDAQ: DOX) is a global software and services provider specializing in solutions for communications, media and entertainment companies. The company designs, develops and integrates revenue management, customer experience and digital services platforms that enable service providers to launch and monetize new offerings, streamline operations and enhance subscriber engagement. Amdocs’ product suite encompasses billing and order management, customer relationship management, digital commerce and network function virtualization, supported by professional services for implementation, integration and managed operations.
Founded in 1982 and structured as a separate public company in 1998, Amdocs has its corporate headquarters in Chesterfield, Missouri, and maintains major development centers in Ra’anana, Israel.
See Also
- Five stocks we like better than Amdocs
- 3 Low-P/E Stocks That Look Cheap as the S&P 500 Trades Near Record Highs
- Travel + Leisure Goes Big—Is It Ready to Rally?
- 2 Biotech Stocks Shaping Up for Major Breakouts
- 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs
Receive News & Ratings for Amdocs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amdocs and related companies with MarketBeat.com's FREE daily email newsletter.
